Revolution Medicines ships pancreatic cancer drug under FDA early access program
The Story
Revolution Medicines has started shipping its experimental pancreatic cancer drug daraxonrasib to physicians under an FDA-authorized early access program, CEO Mark Goldsmith said. The drug, not yet approved, showed in a Phase 3 trial that patients lived nearly twice as long as those on standard chemotherapy.
Key Facts
- Revolution Medicines began shipping daraxonrasib under an FDA-authorized early access program.
- CEO Mark Goldsmith announced the shipping on Friday evening at a STAT event during the American Society of Clinical Oncology annual meeting.
- The drug is not yet approved.
- A Phase 3 trial reported in mid-April showed patients on daraxonrasib lived nearly twice as long as those on standard chemotherapy.
Conflicting Reports
No conflicting reports identified in the source article.
Still Unclear
No open questions identified in the source article.
Misconceptions
No widespread misconceptions addressed in the source article.
Key Figures
- Mark Goldsmith: CEO of Revolution Medicines.
- Revolution Medicines: biotech company.
- Food and Drug Administration (FDA): authorized the early access program.
- daraxonrasib: experimental pancreatic cancer drug.
- American Society of Clinical Oncology (ASCO): annual meeting where announcement was made.
Sources: statnews.com
